000			01393 a2200385 4500
005			20250513103341.0
264		0	_c19970311
008			199703s 0 0 eng d
022			_a0271-0749
024	7		_a10.1097/00004714-199610000-00009 _2doi
040			_aNLM _beng _cNLM
100	1		_aSandor, P
245	0	0	_aRemoxipride in the treatment of levodopa-induced psychosis. _h[electronic resource]
260			_bJournal of clinical psychopharmacology _cOct 1996
300			_a395-9 p. _bdigital
500			_aPublication Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntiparkinson Agents _xadverse effects
650	0	4	_aAntipsychotic Agents _xtherapeutic use
650	0	4	_aDopamine Antagonists _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLevodopa _xadverse effects
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMotor Skills _xdrug effects
650	0	4	_aParkinson Disease _xdrug therapy
650	0	4	_aPsychoses, Substance-Induced _xdrug therapy
650	0	4	_aRemoxipride _xtherapeutic use
700	1		_aLang, A E
700	1		_aSingal, S
700	1		_aAngus, C
773	0		_tJournal of clinical psychopharmacology _gvol. 16 _gno. 5 _gp. 395-9
856	4	0	_uhttps://doi.org/10.1097/00004714-199610000-00009 _zAvailable from publisher's website
999			_c8882558 _d8882558